{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:02:37Z","timestamp":1761991357228,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jgar.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:37:38Z","timestamp":1660869458000},"page":"98-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5216","authenticated-orcid":false,"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Streit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrin","family":"Tulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Antibiotic resisance threats in the United States, 2019 (2019 AR Threats Report)","key":"10.1016\/j.jgar.2022.08.009_bib0001"},{"year":"2017","series-title":"Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities","key":"10.1016\/j.jgar.2022.08.009_bib0002"},{"key":"10.1016\/j.jgar.2022.08.009_bib0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1017\/ice.2019.2","article-title":"Health and economic burden of antimicrobial-resistant infections in Australian hospitals: a population-based model","volume":"40","author":"Wozniak","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2022.08.009_bib0004","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2022.08.009_bib0005","first-page":"e02125","article-title":"Activity of ceftolozane-tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"year":"2020","series-title":"ZERBAXA (R) (ceftolozane tazobactam) Prescribing Information","key":"10.1016\/j.jgar.2022.08.009_bib0006"},{"key":"10.1016\/j.jgar.2022.08.009_bib0007","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"year":"2018","series-title":"M07 11th edition. Methods for dilution antimicrobial susceptibiity tests for bacteria that grow aerobically","key":"10.1016\/j.jgar.2022.08.009_bib0008"},{"year":"2022","series-title":"M100 32nd edition. Performance standards for antimicrobial susceptibility testing","key":"10.1016\/j.jgar.2022.08.009_bib0009"},{"key":"10.1016\/j.jgar.2022.08.009_bib0010","unstructured":"EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, v12.0, 2022."},{"key":"10.1016\/j.jgar.2022.08.009_bib0011","unstructured":"EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters v10.0, 2020."},{"key":"10.1016\/j.jgar.2022.08.009_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.08.009_bib0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013\u20132015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"year":"2021","series-title":"AURA 2021: fourth Australian report on antimicrobial use and resisatnce in human health","key":"10.1016\/j.jgar.2022.08.009_bib0014"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:06Z","timestamp":1761991146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522002004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":14,"alternative-id":["S2213716522002004"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}